Clinical trials: Men
Benign Prostatic Hyperplasia, Erectile Dysfunction
The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction
The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active…
- Trial name
- NCT02862483
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Healthy
A Study in Healthy Men to Test How BI 474121 is Tolerated
Safety, tolerability, and pharmacokinetics of BI 474121 will be assessed in healthy Japanese male using single rising oral doses in order to provide the basis for an ongoing clinical development of BI 474121 for the treatment of…
- Trial name
- NCT04964453
- Testing
- BI 474121
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Osteoporosis
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent…
- Trial name
- MOVE (NCT00887354)
- Testing
- Teriparatide, Risedronate, Calcium
- Where
- 28 sites in United States, Canada and 10 more
- Volunteers
- 224 people
- Sponsor
- Eli Lilly and Company
Secondary Hypogonadism
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with…
- Trial name
- NCT01270841
- Testing
- topical testosterone, Androxal
- Where
- 18 sites in United States
- Volunteers
- 83 people
- Sponsor
- Repros Therapeutics Inc.
Healthy
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.
- Trial name
- NCT05262751
- Testing
- Ofev®, Nintedanib formulation 1, Nintedanib formulation 2
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Metabolic Effect of High-protein Meals in Men
The purpose of the clinical study is to investigate the effect of the protein quality of high-protein meal replacements on the management of post-prandial blood glucose in healthy men.
- Trial name
- OPTI-PROT (NCT00712010)
- Testing
- Whey protein native, Whey protein microgels, Hydrolyzed whey protein
- Where
- Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Erectile Dysfunction
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
- Trial name
- NCT00229073
- Testing
- dapoxetine
- Volunteers
- 1,116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Kidney Disease and Systemic Inflammation
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
This study is conducted to see how the ziltivekimab works in the body of Chinese people with chronic kidney disease and systemic inflammation.
- Trial name
- NCT05379829
- Testing
- Ziltivekimab
- Where
- 7 sites in China
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Erectile Dysfunction
Primary Care ERectile Function Outcome Registry for Men
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan.
- Trial name
- PERFORM (NCT07356609)
- Volunteers
- 255 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Erectile Dysfunction
Effect of Tadalafil Once a Day in Men With Erectile Dysfunction
The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors.
- Trial name
- NCT00836693
- Testing
- tadalafil
- Where
- 21 sites in Germany, Greece and 3 more
- Volunteers
- 217 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
Main objectives are to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of different dose escalation schemes of BI 456906 in healthy Japanese male subject with BMI 23-40 kg/m2 and to determine a dose…
- Trial name
- NCT04384081
- Testing
- BI 456906
- Where
- Japan
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.
- Trial name
- NCT00691899
- Testing
- odanacatib
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line…
- Trial name
- SYNERGY (NCT01188187)
- Testing
- Custirsen, Docetaxel, Prednisone
- Where
- 140 sites in United States, Belgium and 10 more
- Volunteers
- 1,022 people
- Sponsor
- Achieve Life Sciences
Hypogonadism
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
- Trial name
- NCT01323140
- Testing
- testosterone matrix transdermal system
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Watson Pharmaceuticals
Prostate Cancer
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen…
- Trial name
- STRIVE (NCT01664923)
- Testing
- Enzalutamide, Bicalutamide
- Where
- 109 sites in United States
- Volunteers
- 396 people
- Sponsor
- Pfizer
Healthy
A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3810477 in healthy male subjects.
- Trial name
- NCT06631430
- Testing
- BI 3810477
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim